tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
0RA9 Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings0RA9 Upcoming Earnings Report: What to Expect?
24d ago
Abivax’s Promising Phase 2b Study on Obefazimod for Crohn’s Disease
Premium
Company Announcements
Abivax’s Promising Phase 2b Study on Obefazimod for Crohn’s Disease
1M ago
Abivax’s Promising Phase 2b Study on Obefazimod for Crohn’s Disease: Market Implications
Premium
Company Announcements
Abivax’s Promising Phase 2b Study on Obefazimod for Crohn’s Disease: Market Implications
2M ago
Abivax SA’s Obefazimod: Strong Phase 3 Results and Promising Market Potential Justify Buy Rating
PremiumRatingsAbivax SA’s Obefazimod: Strong Phase 3 Results and Promising Market Potential Justify Buy Rating
2M ago
Abivax announces trading resumption of shares on Euronext Paris
Premium
The Fly
Abivax announces trading resumption of shares on Euronext Paris
2M ago
Abivax $400M Spot Secondary; price range $62.50-$65.00
Premium
The Fly
Abivax $400M Spot Secondary; price range $62.50-$65.00
2M ago
Abivax upgraded to Overweight at Morgan Stanley after obefazimod data
PremiumThe FlyAbivax upgraded to Overweight at Morgan Stanley after obefazimod data
2M ago
Abivax price target raised to $101 from $50 at Guggenheim
Premium
The Fly
Abivax price target raised to $101 from $50 at Guggenheim
2M ago
Abivax price target raised to $70 from $42 at Piper Sandler
Premium
The Fly
Abivax price target raised to $70 from $42 at Piper Sandler
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100